Hyper-CVAD Treatment in Lymphoblastic Lymphoma

• Conditions: Lymphoblastic Lymphoma

• Registration Number: NCT01813344
• Lead Sponsor: Ajou University School of Medicine

Brief Summary

Treatment outcomes of lymphoblastic lymphoma (LBL) have improved by the use of the regimens for acute lymphoblastic leukemia. Hyper-CVAD is one of the most effective treatments with high remission rate in acute lymphoblastic leukemia (ALL) and LBL. However, the treatment outcome of hyper-CVAD in LBL has reported only in small number of patients from single institution. The investigators conducted this study to evaluate the hyper-CVAD regimen based treatment in LBL.

Detailed Description

We will analyze treatment outcome of lymphoblastic lymphoma patients treated with hyper-CVAD regimen from 13 institutions in Korea. In all patients, hyper-CVAD was initial treatment. After achievement of response, patients either underwent hematopoietic stem cell transplantation (HSCT) or consolidation with hyper-CVAD.

Study Timeline

• Study Start: 2012-01
• Status Verified: 2013-03
• Study First Submitted: 2013-03-13
• Study First Submitted QC: 2013-03-14
• Last Update Submitted: 2013-03-14
• Study First Posted: 2013-03-19
• Last Update Posted: 2013-03-19
• Primary Completion: 2013-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• age over 18 at diagnosis
• Pathologically proven lymphoblastic lymphoma

Exclusion Criteria

• proven HIV infection
• pretreatment with other regimens

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival	3-year
Progression free survival	3-year

Secondary Outcome Measures

Name	Time	Method
Response Rate	24 weeks

Trial Locations

Locations (1)

Ajou Universtiy School of Medicine; 🇰🇷 Suwon, Kyeonggi, Korea, Republic of